Erratum.
- Published in:
- 2023
- Publication type:
- Correction Notice
Works matching IS 09066705 AND DT 2023 AND VI 32 AND IP 3
Results: 10
1
2
Clues for developing next‐generation cancer immunotherapy.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 238, doi. 10.1111/exd.14751
- By:
- Publication type:
- Article
3
Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 264, doi. 10.1111/exd.14750
- By:
- Publication type:
- Article
4
Melanoma antigens recognized by T cells and their use for immunotherapy.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 297, doi. 10.1111/exd.14741
- By:
- Publication type:
- Article
5
Future prospects for cancer immunotherapy using induced pluripotent stem cell‐derived dendritic cells or macrophages.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 290, doi. 10.1111/exd.14729
- By:
- Publication type:
- Article
6
Immune checkpoint inhibitor‐based therapy for advanced acral and mucosal melanoma.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 276, doi. 10.1111/exd.14725
- By:
- Publication type:
- Article
7
Significance of regulatory T cells in cancer immunology and immunotherapy.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 256, doi. 10.1111/exd.14721
- By:
- Publication type:
- Article
8
Resistance to immune checkpoint inhibitors and the tumor microenvironment.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 240, doi. 10.1111/exd.14716
- By:
- Publication type:
- Article
9
Adoptive cell transfer therapy for melanoma.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 250, doi. 10.1111/exd.14707
- By:
- Publication type:
- Article
10
Issue Information.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 3, p. 235, doi. 10.1111/exd.14590
- Publication type:
- Article